Biotech | December 11, 2021
Alembic acquires stake in RIGlmmune
The company is focused on the development of novel treatments for RNA viruses
The company is focused on the development of novel treatments for RNA viruses
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Subscribe To Our Newsletter & Stay Updated
